Genmab A/S (NASDAQ:GMAB) Receives $39.17 Consensus Price Target from Analysts
Genmab A/S (NASDAQ:GMAB – Get Free Report) has been assigned a consensus recommendation of “Moderate Buy” from the thirteen research firms that are covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, three have given a hold recommendation, eight have given a buy recommendation and one has […]
Genmab A/S (NASDAQ:GMAB – Get Free Report) has been assigned a consensus recommendation of “Moderate Buy” from the thirteen research firms that are covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, three have given a hold recommendation, eight have given a buy recommendation and one has […]
